Hypoxia in Hepatocellular Carcinoma.
- Author:
Sun Jung MYUNG
1
;
Jung Hwan YOON
Author Information
1. Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. yoonjh@snu.ac.kr
- Publication Type:Review ; English Abstract
- Keywords:
Carcinoma, hepatocellular;
Angiogenesis inducing agent;
Angiogenesis inhibitors;
Hypoxia
- MeSH:
Angiogenesis Inhibitors/*therapeutic use;
Carcinoma, Hepatocellular/*drug therapy;
Cell Hypoxia;
Disease Progression;
Humans;
Liver Neoplasms/*drug therapy
- From:The Korean Journal of Hepatology
2007;13(1):9-19
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hepatocellular carcinoma (HCC) is characterized by hypervascularity, indicating that angiogenesis plays a vital role in HCC growth and progression. A number of anti-angiogenic therapies are being utilized in clinical trials in patients with HCC. However, the therapeutic efficacy of anti-angiogenic monotherapy is still insufficient. While inhibition of angiogenesis results in tumor hypoxia and cell death, this inhibition may also activate hypoxia-induced cell signals that may promote HCC progression. Therefore, an understanding of these signals may be essential in designing efficient anti-angiogenic therapies. This review summarizes the role of hypoxia-induced signals in HCC.
